Abstract
CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/s2152-2650(23)01145-x
Copy DOIPublication Date: Aug 31, 2023 |
CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
Join us for a 30 min session where you can share your feedback and ask us any queries you have